Oral Capecitabine Achieves Response in MetastaticEccrine Carcinoma

+e low prevalence rate and limited literature on eccrine carcinoma (EC) pose a challenge to properly diagnosing and treating thisrare malignancy. EC lesions tend to present similarly to other cutaneous neoplasms and dermatitis-like conditions. Efficacioustreatment guidelines have not been established for patients diagnosed with EC, and few treatment regimens have demonstratedclinical benefit. Due to the high metastatic potential of EC, recognizing the clinical presentation, properly diagnosing, and utilizingbeneficial treatment options are important for managing this disease. We report a case of a 66-year-old female who presented withlesions that her primary care provider misdiagnosed as basal cell carcinoma. +e disease responded poorly to taxane- andplatinum-based chemotherapies as well as an isolated limb perfusion of an alkylating agent. However, continuous dosing of oralcapecitabine achieved an 18-month period of progression free survival (PFS) and ameliorated quality of life. We wish to highlightthis rare disease and discuss presentation, diagnosis, and management as it is most often misdiagnosed leading to advancedmetastatic disease when patients present to the oncologist. In addition, it is crucial to study and report potentially efficaciousregimens considering the lack of clinical trials in this disease.